Growing concerns have led to Health Canada announcing a Xeljanz safety review, to determine whether more warnings or actions are needed following studies suggesting the ulcerative colitis drug could increase the risk of cancer and heart attacks.…
New Xeljanz research links the drug to cancer risks, but has not yet led to a warning for users as to which types of cancer they may face.…
The FDA may be delaying approval for the drug Rinvoq to be used as a psoriatic arthritis drug due to its close ties to Xeljanz, which has been linked to heart risk and cancer concerns.
…
Pfizer filed a patent lawsuit over an alleged attempt to create a generic version of Xeljanz shortly after the FDA announced new concerns about the drug’s safety.…
The FDA is weighing new restrictions on Xeljanz, following clinical trial data linking the drug to an increased risk of heart problems and cancer, according to a new report.…
A new FDA warning indicates Xeljanz side effects may increase the risk of heart problems, including heart attacks, and cancer in patients over 50.…
Side effects of the rheumatoid arthritis and ulcerative colitis drug Xeljanz may result in the development of serious and potentially lethal pulmonary embolism. Lawsuits are being reviewed by lawyers nationwide.…
A new study finds that aspirin is just as safe and effective as more powerful blood thinners at preventing life-threatening blood clots following surgery, but is far more cost effective.…
The FDA has approved higher dose formulations of extended release Xeljanz, despite concerns over the risk of potentially fatal blood clots.…
European regulators warn that Xeljanz should not be given to any patients at high risk of blood clots unless absolutely necessary.…
